NCT07353957撤回2 期
A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer in Combination With Pembrolizumab as First-Line Treatment
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- Merus B.V.
- 入组人数
- 180
- 试验地点
- 24
研究概览
简要总结
The study will test the efficacy and safety of petosemtamab in combination with Pembrolizumab in first line patients with squamous non-small cell lung cancer and non-squamous non-small cell lung cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to provide written informed consent and is willing and able to comply with all study procedures and contraception requirements
- •Age ≥ 18 years at the signing of ICF
- •At least 1 measurable lesion as defined by RECIST 1.1
- •ECOG performance status of 0 or 1
- •Life expectancy ≥ 12 weeks, in the opinion of the Investigator
- •Adequate hematologic function
- •Creatinine clearance ≥ 60 mL/min calculated according to the Cockroft and Gault formula
- •Adequate liver function
- •Serum albumin ≥ 3 g/dL
- •Serum magnesium and corrected calcium, Grade ≤ 1 alteration
- •Participants of childbearing potential must agree to use highly effective contraception methods for the duration of study participation
- •Histologically confirmed metastatic (Stage IV) sqNSCLC with PD-L1 TPS ≥ 50%
- •No prior systemic treatment for metastatic disease
- •Testing is required per local SOC and availability of testing to document absence of actionable genomic tumor aberrations
- •Histologically confirmed metastatic (Stage IV) non-squamous NSCLC with PD-L1 TPS ≥ 50%
排除标准
- •Has untreated CNS metastases and/or carcinomatous meningitis
- •Participation in an interventional clinical study with any investigational drug within 4 weeks prior to the first dose of study treatment OR participation in any clinical study with petosemtamab at any time prior to the first dose of study treatment, regardless of whether petosemtamab was received
- •Participants who received prior treatment with a PD-(L)1 inhibitor
- •Participants who have received prior systemic chemotherapy, targeted or biological antineoplastic therapy for metastatic NSCLC
- •Any systemic anticancer therapy within 4 weeks prior to the first dose of study treatment
- •Major surgery or radiotherapy within 3 weeks prior to the first dose of study treatment. Participants who received prior radiotherapy to ≥ 25% of bone marrow are not eligible, regardless of when it was received.
- •Persistent Grade > 1 clinically significant toxicities related to prior antineoplastic therapies using NCI-CTCAE v5.0
- •History of hypersensitivity reaction to any of the excipients of petosemtamab or pembrolizumab
- •Unstable angina; history of congestive heart failure of Class II-IV New York Heart Association criteria or serious cardiac arrhythmia requiring treatment (except atrial fibrillation, paroxysmal supraventricular tachycardia); or history of myocardial infarction within 6 months prior to the first dose of study treatment
- •History of prior malignancies within the last 5 years, with the exception of excised local cancer
- •Current dyspnea at rest of any origin or other diseases requiring continuous oxygen therapy, including participants with a history of ILD (eg, pneumonitis or pulmonary fibrosis) or evidence of ILD on baseline chest CT scan
- •Current serious illness or medical condition, including but not limited to uncontrolled active infection and clinically significant pulmonary, metabolic, or psychiatric disorders
- •Known infectious disease
- •Participants who are pregnant or breastfeeding.
研究组 & 干预措施
First line non-squamous non-small cell lung cancer patients
Experimental
干预措施: Petosemtamab + Pembrolizumab (Combination Product)
First line squamous non-small cell lung cancer patients
Experimental
干预措施: Petosemtamab + Pembrolizumab (Combination Product)
研究者
研究点 (24)
Loading locations...
相似试验
招募中
2 期
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizumab) and
immunotherapy ( Pembrolizumab)2024-515788-73-00Fondation Franc.Cancerologie Digestive55
Enrolling By Invitation
早期 1 期
Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction AdenocarcinomaNCT07356466Fujian Medical University100
招募中
2 期
Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentNCT07275216City of Hope Medical Center23
招募中
3 期
Pembrolizumab Monotherapy versus Sacituzumab Govitecan in Combination with MK‑3475 for PD-L1 TPS ≥50% Metastatic NSCLC2023-503501-11-00Merck Sharp & Dohme LLC166
招募中
2 期
Phase II, open label, single arm study of PembrolizumAb combiNeD with cisplatin or carbOplatin and etoposide in treatment naïve advanced meRkel cell cArcinoma (MCC) (PANDORA Trial).2022-500988-12-00Fondazione IRCCS Istituto Nazionale Dei Tumori35